Veracyte (VCYT) investor relations material

Second quarter highlights and financial performance

• Achieved $150 million in revenue for Q2, leading to an upward revision of guidance for the year.

• Adjusted EBITDA margin exceeded 29%, with over $40 million in cash generated.

• Revenue growth projected at 14%-16% for the year, with a focus on sustaining a 25% adjusted EBITDA margin.

• Active portfolio management led to discontinuation of five products, focusing on high-ROIC franchises.

• Afirma guidance updated to 12%-14% revenue growth, supported by ASP gains and operational improvements.

Product launches and pipeline developments

• Launched Prosigna for breast cancer and TrueMRD for muscle-invasive bladder cancer (MIBC) in Q2.

• Prosigna now offered in the U.S. CLIA lab, with strong OPTIMA trial data supporting its differentiation.

• TrueMRD leverages whole genome sequencing, targeting MIBC initially, with plans for broader indications.

• Decipher continues to grow, with 17% volume growth in Q2, despite guideline changes impacting low-risk segment.

• Ongoing trials in low-risk prostate cancer may support future guideline inclusion and growth.

Strategic focus and market positioning

• Emphasis on high-ROIC investments, particularly in Decipher, Afirma, MRD, and Prosigna franchises.

• Prosigna aims to gain share in a mature market through recent compelling clinical data.

• TrueMRD positioned for differentiation in MRD market, leveraging scientific rigor and commercial relationships.

• International expansion focuses on Prosigna, with Decipher as a longer-term opportunity.

• Capital allocation prioritizes internal and organic investment, followed by M&A and buybacks.